⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14318100 | 1.00 | — | — | |
| SCHEMBL25662386 | 0.78 | — | — | |
| SCHEMBL26431620 | 0.78 | — | — | |
| SCHEMBL27527664 | 0.78 | — | — | |
| SCHEMBL23446809 | 0.78 | — | — | |
| SCHEMBL24312311 | 0.78 | — | — | |
| SCHEMBL25660751 | 0.78 | — | — | |
| SCHEMBL12648317 | 0.74 | — | — | |
| SCHEMBL8092756 | 0.74 | ADH1B (0.41) | — | |
| SCHEMBL18098502 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021200-B1 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | BASF AG (DE) | 2002-02-06 | — | — | EP | claimed |
| US-20010009901-A1 | Antineoplastic peptides | BASF AKTIENGESELLSCHAFT GERMANY | 2001-07-26 | — | — | US | claimed |
| EP-0866800-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-30 | — | — | EP | claimed |
| WO-1997022621-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-26 | — | — | WO | claimed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-02-21 | — | — | US | disclosed |
| US-8163698-B2 | Dolastatin 15 derivatives | ABBOTT GMBH & CO. KG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-7662786-B2 | oligopeptides; anticarcinogenic agent; good water solubility and cost effective; , B, D, E, F, G and K are alpha -amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as,an amino group, an N-substituted amino group, a beta -hydroxylamino group, an alkoxy group | ABBOTT GMBH & CO. KG (DE) | 2010-02-16 | — | — | US | disclosed |
| EP-1593686-A1 | Antineoplastic peptides | Abbott GmbH & Co. KG (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-20030153505-A1 | Dolastatin 15 derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-14 | — | — | US | disclosed |
| US-6458765-B1 | POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| EP-1021200-B1 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | BASF AG (DE) | 2002-02-06 | — | — | EP | disclosed |
| US-20010009901-A1 | Antineoplastic peptides | BASF AKTIENGESELLSCHAFT GERMANY | 2001-07-26 | — | — | US | disclosed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
| EP-0866800-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997022621-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-26 | — | — | WO | disclosed |